MECHANISMS OF ULTRASOUND ENHANCED THROMBOLYSIS

Information

  • Research Project
  • 6017315
  • ApplicationId
    6017315
  • Core Project Number
    R42HL060468
  • Full Project Number
    2R42HL060468-02
  • Serial Number
    60468
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1998 - 26 years ago
  • Project End Date
    8/31/2001 - 23 years ago
  • Program Officer Name
  • Budget Start Date
    9/22/1999 - 25 years ago
  • Budget End Date
    8/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/21/1999 - 25 years ago
Organizations

MECHANISMS OF ULTRASOUND ENHANCED THROMBOLYSIS

DESCRIPTION (Adapted from Applicant's Abstract): The applicant organization, EKOS, has developed a drug delivery catheter device that utilizes low energy ultrasound to enhance drug-mediated thrombolysis. Despite the progress in animal studies and human trials, the underlying acoustic and biochemical mechanisms for the enhancement of thrombolysis are not fully understood. The applicants hypothesized ultrasound can enhance thrombolysis further than currently observed, but new experimental assays and models are needed in order to optimize the effects of the ultrasound and to better understand the fundamental mechanisms. In Phase II, the applicants proposed to continue to investigate acoustic mechanisms of thrombolysis and acoustic protocols that may further enhance thrombolysis by characterization of kinetic and transport parameters in well defined and controlled experiments. In addition, they proposed to focus on the mechanisms by which microbubbles further enhance the ultrasound-mediated thrombolytic process. This has been shown in vitro and in vivo but there is little understanding of how best to use microbubbles to maximize their synergistic effect with ultrasound in a therapeutic rather than diagnostic mode. These studies are critical to determining how the EKOS ultrasound catheter can be optimized for use in human patients as well as to provide insight into the development of future thrombolytic products. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R42
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    EKOS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98011
  • Organization District
    UNITED STATES